Sab Biotherapeutics, Inc. · NASDAQ:SABS

Sab Biotherapeutics — Technical Presentation (September 2022)

12 slides from Sab Biotherapeutics's technical presentation, Sep 28, 2022

  1. Slide 1: Efficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic

    Efficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase 2a, Randomized, Double-Blind Trial in H1N1 Challenged Adults Thomas C. Luke, MD. Senior Vice President, Research and Development SAB Biotherapeutics, Inc. *As an employee, Dr. Luke has a potential financia

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements 2 The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (“SAB”) and is general background information about SAB’s activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete

  3. Slide 3: Targeted Product Profile and Administration Routes

    Targeted Product Profile and Administration Routes 3 © 2022 SAB BIOTHERAPEUTICS, INC. Treat high-risk influenza adult patients prior to the development of severe disease: Adults 65 years of age and older Immunocompromised due to a disease or medications (autoimmune, cancer, etc.) Patients with respi

  4. Slide 4: DiversitAb Development Process for SAB-176

    4 © 2022 SAB BIOTHERAPEUTICS, INC. DiversitAb™ Development Process for SAB-176 Continue Vaccinations & Collections Tc Bovine™ Vaccination WEEK Vaccinate Every Three Weeks Fully Human Polyclonal Antibodies 0 1 2 3 4 5 6 7 8 9 10 11 12 V3 D14 Purified human polyclonal IgG designed to specifically bind

  5. Slide 5: SAB-176 had Higher HAI Titers than Anti-Flu hIVIGs Against Multiple Influenza Strains

    © 2022 SAB BIOTHERAPEUTICS, INC. – CONFIDENTIAL SAB-176 had Higher HAI Titers than Anti-Flu hIVIGs Against Multiple Influenza Vaccine Strains and Non-Vaccine Strains Dr. Victor Huber, University of South Dakota

  6. Slide 6: Trial Design and Methods

    Trial Design and Methods 6 © 2022 SAB BIOTHERAPEUTICS, INC. The trial was sponsored by SAB Biotherapeutics and designed with hVIVO Services Limited. The study was conducted at hVIVO Services Limited screening and quarantine facilities in London, England. (EudraCT reference number 2021-001254-56 and

  7. Slide 7: Primary and Selected Secondary Outcome Measures

    Primary and Selected Secondary Outcome Measures 7 © 2022 SAB BIOTHERAPEUTICS, INC. Primary Outcome Measure: Area under the viral load-time curve (VL-AUC) of Influenza A/California/2009 H1N1 virus as determined by qRT-PCR on nasal samples of SAB-176 when compared to placebo. [Time Frame: 8 Days ] Sel

  8. Slide 8: Disposition of Participants

    Disposition of Participants 8 © 2022 SAB BIOTHERAPEUTICS, INC.

  9. Slide 9: SAB-176 Met the Primary Endpoint of Viral Load and Secondary Endpoint of Symptom Reduction

    SAB-176 Met the Primary Endpoint of Viral Load and Secondary Endpoint of Symptom Reduction Achieved Statistically Significant (p = 0.026) Reduction in Viral Load Mean Viral Load by Nasal Samples qRT-qPCR by Day Relative to Viral Challenge 9 Mean Total Symptom Score by Day Relative to Viral Challenge

  10. Slide 10: Kaplan-Meier Time to Resolution of Positive Viral Cultures

    10 © 2022 SAB BIOTHERAPEUTICS, INC. Kaplan-Meier Time to Resolution of Positive Viral Cultures Following First Positive Culture Starting 2 Days After Intranasal Viral Challenge Shortened time of viral shedding, as measured by lack of culturable virus.

  11. Slide 11: Conclusions

    11 © 2022 SAB BIOTHERAPEUTICS, INC. Conclusions SAB-176: a novel anti-Type A and B influenza polyclonal immunotherapeutic Demonstrates significant HAI titers to multiple Type A and B influenza strains Met primary endpoint of reducing nasopharyngeal viral load as determined by qRT-PCR Met secondary e

  12. Slide 12: Acknowledgements

    12 © 2022 SAB BIOTHERAPEUTICS, INC. Acknowledgements SAB Biotherapeutics, Inc., would like to acknowledge the support of Dr. Victor Huber, University of South Dakota, for HAI assessment of influenza strains. SAB Biotherapeutics, Inc., would like to acknowledge Dr. Alex Mann, Dr. Victoria Parker, Mr.

SAB Biotherapeutics — Technical Presentation (September 2022) on 6ix